BioCardia Inc. (NASDAQ: BCDA)
$1.9700
+0.1300 ( +2.07% ) 28.4K
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Market Data
Open
$1.9700
Previous close
$1.8400
Volume
28.4K
Market cap
$8.89M
Day range
$1.9150 - $2.0500
52 week range
$1.6250 - $10.7895
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jul 17, 2024 |
8-k | 8K-related | 15 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jul 02, 2024 |
4 | Insider transactions | 1 | Jun 24, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 12, 2024 |
8-k | 8K-related | 14 | Jun 10, 2024 |
8-k | 8K-related | 15 | Jun 07, 2024 |
8-k | 8K-related | 15 | May 30, 2024 |
8-k | 8K-related | 15 | May 21, 2024 |